COVID-19 test developed to deliver results in under an hour
CU Boulder researchers have developed a rapid, portable, saliva-based COVID-19 test able to return results in 45 minutes, which could be deployable in community settings like manufacturing facilities and factories.
CU Boulder researchers have developed a rapid, portable, saliva-based COVID-19 test able to return results in 45 minutes. Such a test might eventually be deployable in community settings like factories, manufacturing facilities and other areas where large groups of people congregate. Efforts are underway to conduct further validation tests and seek regulatory approval.
“We are facing a serious testing shortage in this country right now as more people want to get tested and diagnostics labs are overwhelmed,” said Nicholas Meyerson, a postdoctoral associate in the Sawyer Lab at the BioFrontiers Institute at CU Boulder. “We’ve developed a test that could get results to people much faster.”
The test is designed for widespread screening to help identify asymptomatic individuals. Research shows people infected with the virus but with no obvious symptoms make up as many as 70% of cases and can still spread disease. In this new test, a user spits in a tube, adds a solution to stabilize it then closes the lid and hands it off to testing staff. They process it through a simple system requiring little more than pipettes, a heating source and an enzyme mixture.
If the sample turns from pink to yellow, the test is positive. If it doesn’t, it’s negative.
Because no swabs are required, and no fancy equipment is needed, the tests are less vulnerable to backlogs and supply chain shortages, the researchers say.
“Every test that has been approved to date requires that the sample, even if it’s saliva, be processed in a clinical diagnostic lab or at a doctor’s office, using sophisticated equipment. That can take up to nine days right now,” said Professor Sara Sawyer, a virologist in the Department of Molecular Cellular and Developmental Biology who led the development of the test.
Frequent, fast testing key to curbing spread
The test is based on a 20-year-old technology known as reverse transcription loop-mediated isothermal amplification (RT-LAMP) previously used, for instance, to screen mosquitoes for the Zika virus in remote regions of South America.
Once a sample is collected, it is heated to liberate any viral genome present in the test liquid. This sample is then added to three tubes, each containing a custom enzyme mixture which, when heated to a certain temperature, undergoes a chemical reaction when the genetic material from SARS-CoV-2 is detected. That’s the virus that causes COVID-19.
In one experiment described in the paper, the researchers conducted what is known as a “contrived clinical validation.” One researcher spiked 30 out of 60 saliva samples with inactivated SARS-CoV-2 in the lab. Then they shuffled the samples and gave them to another scientist to test with the RT-LAMP technology.
“The test predicted with 100% accuracy all of the negative samples, and 29 of 30 positive samples were predicted accurately,” said Meyerson, noting that the 30th test was scored as inconclusive. Additional second-party validation tests are currently underway.
The authors note that the test is slightly less sensitive than those performed in clinical labs. But a separate computer modeling study, also by researchers at the BioFrontiers Institute, found that quick turnaround for testing is even more critical to curbing the pandemic than test sensitivity is.
“Our modeling showed that whether a test is sensitive or super-sensitive is not that important,” said BioFrontiers Director Roy Parker, co-author of their research paper, which has not yet been peer reviewed. “What is important is frequent testing, with the test results returned as fast as possible, which identifies more infected people faster and can limit new infections.”
The team sees the test as a “triaging tool.”
“Those who test positive could quarantine themselves as they await confirmatory testing,” said Sawyer.
The research team, in cooperation with Venture Partners at CU Boulder, has created a spinoff company, Darwin Biosciences, to commercialize the test. The test has not been approved by the Food and Drug Administration yet, but the team has submitted paperwork via the agency’s Emergency Use Authorization program. The team is also working with the state to carry out further validation tests locally and, pending those results, expedite regulatory clearance for use in Colorado.
– Edited by Chris Vavra, associate editor, Control Engineering, CFE Media and Technology, firstname.lastname@example.org.